Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
Orchestra BioMed (OBIO) announced an R&D Day on November 12, 2026, in New York City with a live webcast, covering AVIM Therapy and Virtue SAB clinical programs. Medtronic is Orchestra BioMed's strategic collaboration partner for developing and commercializing AVIM Therapy for uncontrolled hypertension in pacemaker-indicated patients.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.